Literature DB >> 22988701

Early diagnosis improves survival in colorectal cancer.

Margaret G Keane1, Gavin J Johnson.   

Abstract

Colorectal cancer is the second most common cause of death from cancer in the UK. Common alarm symptoms include rectal bleeding, change in bowel habit and iron deficiency anaemia. Abdominal mass, weight loss, nausea and vomiting, anorexia and abdominal swelling are less common presenting symptoms. Patients meeting the NICE criteria for urgent referral should be referred via the two week wait pathway to the local colorectal department for prompt assessment to exclude colorectal cancer. Colorectal cancer has a male predominance and is strongly associated with age; 80% of new cases occur in patients aged over 60. Obesity and limited exercise are strong risk factors. Diets low in fruit and vegetables and fibre and high in red meat have also been associated with an increased risk. Patients with one first-degree relative under 45 or two first-degree relatives of any age have an approximate lifetime risk of developing colorectal cancer of 16-25% in men and 10-15% in women. Having one first-degree relative who developed the disease after the age of 65 barely increases lifetime risk. Patients with ulcerative colitis and Crohn's colitis also have an increased lifetime risk of colorectal cancer. In the NHS Bowel Cancer Screening Programme, patients are screened with a faecal occult blood test which they complete at home and return by post. Patients with positive tests are then offered further investigation, typically colonoscopy. The sensitivity of colonoscopy for detecting abnormalities is > 90% and hence it is the gold standard test for evaluating the large bowel. Once a diagnosis of colorectal cancer has been confirmed, the extent of disease is evaluated by a CT scan of the chest, abdomen and pelvis.

Entities:  

Mesh:

Year:  2012        PMID: 22988701

Source DB:  PubMed          Journal:  Practitioner        ISSN: 0032-6518


  10 in total

Review 1.  Evolving notions on immune response in colorectal cancer and their implications for biomarker development.

Authors:  Fabio Grizzi; Gianluca Basso; Elena Monica Borroni; Tommaso Cavalleri; Paolo Bianchi; Sanja Stifter; Maurizio Chiriva-Internati; Alberto Malesci; Luigi Laghi
Journal:  Inflamm Res       Date:  2018-01-10       Impact factor: 4.575

2.  A symptom-based model to predict colorectal cancer in low-resource countries: Results from a prospective study of patients at high risk for colorectal cancer.

Authors:  Olusegun Isaac Alatise; Omobolaji O Ayandipo; Ademola Adeyeye; Ken Seier; Akinwunmi O Komolafe; Matthew O Bojuwoye; Oludapo O Afuwape; Ann Zauber; Adeleye Omisore; Samuel Olatoke; Adegboyega Akere; Olusola Famurewa; Mithat Gonen; David O Irabor; T Peter Kingham
Journal:  Cancer       Date:  2018-04-12       Impact factor: 6.860

3.  Determining the Risk Factors Affecting on Death Due to Colorectal Cancer Progression: Survival Analysis in the Presence of Competing Risks.

Authors:  Malihe Safari; Hossein Mahjub; Habib Esmaeili; Mohammad Abbasi; Ghodratollah Roshanaei
Journal:  J Gastrointest Cancer       Date:  2021-03-03

4.  Colorectal cancer patients exhibit increased levels of galanin in serum and colon tissues.

Authors:  Przemysław Kwiatkowski; Janusz Godlewski; Jacek Kieżun; Bartłomiej Emil Kraziński; Zbigniew Kmieć
Journal:  Oncol Lett       Date:  2016-08-23       Impact factor: 2.967

5.  Profiles of differentially expressed genes and overexpression of NEBL indicates a positive prognosis in patients with colorectal cancer.

Authors:  Xiao Qiu; Jue-Rong Feng; Fan Wang; Peng-Fei Chen; Xiao-Xing Chen; Rui Zhou; Ying Chang; Jing Liu; Qiu Zhao
Journal:  Mol Med Rep       Date:  2017-12-07       Impact factor: 2.952

6.  LASP2 suppresses colorectal cancer progression through JNK/p38 MAPK pathway meditated epithelial-mesenchymal transition.

Authors:  Bin Wang; Lanzhi Zhang; Liying Zhao; Rui Zhou; Yanqing Ding; Guoxin Li; Liang Zhao
Journal:  Cell Commun Signal       Date:  2017-06-12       Impact factor: 5.712

7.  S100A16 suppresses the proliferation, migration and invasion of colorectal cancer cells in part via the JNK/p38 MAPK pathway.

Authors:  Shiyu Ou; Yan Liao; Jie Shi; Jing Tang; Yanqing Ye; Fengfei Wu; Weidong Wang; Jieying Fei; Fang Xie; Lan Bai
Journal:  Mol Med Rep       Date:  2020-12-23       Impact factor: 2.952

8.  Survival of colorectal cancer patients in Brunei Darussalam: comparison between 2002-09 and 2010-17.

Authors:  Shirley H F Lee; Hanif Abdul Rahman; Nadiah Abidin; Sok King Ong; Elvynna Leong; Lin Naing
Journal:  BMC Cancer       Date:  2021-04-30       Impact factor: 4.430

9.  Anti-Tumor Activity of Atractylenolide I in Human Colon Adenocarcinoma In Vitro.

Authors:  Ka Woon Karen Chan; Hau Yin Chung; Wing Shing Ho
Journal:  Molecules       Date:  2020-01-04       Impact factor: 4.411

Review 10.  Postmenopausal women in gynecological care.

Authors:  Magdalena Pertyńska-Marczewska; Tomasz Pertyński
Journal:  Prz Menopauzalny       Date:  2021-06-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.